HOME About Santen News IR Information Products Careers  
 
IR Information
Financial Summary
Financial Documents
IR Events
Stock Information
IR Contact
 
IR Information  > 

Financial Summary
Net Sales of the year ended March 2008 103,394 million Yen Net Income of the year ended March 2008 12,650 million yen
Retrn on Equity(ROE) of the year ended March 2008 9.9% R&D Costs and Ratio of R&D Costs to Net Sales Year ended March 2008 R&D Costs 12,941 million yen Ratio of R&D Costs to Net Sales 12.5%
Sales by Business Segment 82.6% Prescription Ophthalmic Pharmaceuticals 9.3% Prescription Anti-rheumatic Pharmaceuticals 5.3% OTC Pharmaceuticals 0.4% Medical Devices

Back to top

Five-year Summary of Selected Financial Data


Five-year Summary of Selected Financial Data

Note:  The U.S. dollar amounts represent translations of Japanese yen, for convenience only, at the rate of 99.90yen=US$1, the approximate exchange rate at March 31, 2008.


Back to top 		 
Research & Development
Share Price
20-minute delayed share price and charts.
Provided by MONEX, Inc.
Download Adobe® Reader® to view PDF files.
  Get Adobe Reader